Literature DB >> 28436989

Corrigendum: The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication.

Carolina Q Sacramento, Gabrielle R de Melo, Caroline S de Freitas, Natasha Rocha, Lucas Villas Bôas Hoelz, Milene Miranda, Natalia Fintelman-Rodrigues, Andressa Marttorelli, André C Ferreira, Giselle Barbosa-Lima, Juliana L Abrantes, Yasmine Rangel Vieira, Mônica M Bastos, Eduardo de Mello Volotão, Estevão Portela Nunes, Diogo A Tschoeke, Luciana Leomil, Erick Correia Loiola, Pablo Trindade, Stevens K Rehen, Fernando A Bozza, Patrícia T Bozza, Nubia Boechat, Fabiano L Thompson, Ana M B de Filippis, Karin Brüning, Thiago Moreno L Souza.   

Abstract

Entities:  

Year:  2017        PMID: 28436989      PMCID: PMC5402769          DOI: 10.1038/srep46772

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


× No keyword cloud information.
The Competing Financial Interests section in this Article is incorrect and should read: “Dr. Karin Brüning is a member of the BMK consortium, able to produce sofosbuvir”.
  3 in total

Review 1.  Global Alert: Zika Virus-an Emerging Arbovirus.

Authors:  Zulal Ozkurt; Esra Cinar Tanriverdi
Journal:  Eurasian J Med       Date:  2017-06

Review 2.  Advancement in the Development of Therapeutics Against Zika Virus Infection.

Authors:  Kangchen Li; Qianting Ji; Shibo Jiang; Naru Zhang
Journal:  Front Cell Infect Microbiol       Date:  2022-07-08       Impact factor: 6.073

Review 3.  Drug Repurposing for Viral Infectious Diseases: How Far Are We?

Authors:  Beatrice Mercorelli; Giorgio Palù; Arianna Loregian
Journal:  Trends Microbiol       Date:  2018-05-11       Impact factor: 17.079

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.